+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Keratitis - Pipeline Review, H2 2019

  • ID: 4901301
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 78 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AlfaSigma SpA
  • Dobecure SL
  • Eleusis Ltd
  • MimeTech Srl
  • Riptide Bioscience Inc
  • Sinsa Labs Inc
  • MORE
Keratitis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Pipeline Review, H2 2019, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Keratitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 12 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AlfaSigma SpA
  • Dobecure SL
  • Eleusis Ltd
  • MimeTech Srl
  • Riptide Bioscience Inc
  • Sinsa Labs Inc
  • MORE
Introduction
Report Coverage
Keratitis - Overview
Keratitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Keratitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Keratitis - Companies Involved in Therapeutics Development
AlfaSigma SpA
AmebaGone Inc
Cumulus Pharmaceutical LLC
Dobecure SL
Editas Medicine Inc
Eleusis Ltd
EyeGate Pharmaceuticals Inc
Fox Chase Chemical Diversity Center Inc
iVeena LLC
MimeTech Srl
NanoViricides Inc
RegeneRx Biopharmaceuticals Inc
Riptide Bioscience Inc
Shulov Innovative Science Ltd
SIFI SpA
Sinsa Labs Inc
TGV-Inhalonix Inc
Veloce BioPharma LLC
Viraze
Keratitis - Drug Profiles
Keratitis - Dormant Projects
Keratitis - Discontinued Products
Keratitis - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Keratitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Keratitis - Pipeline by AlfaSigma SpA, H2 2019
Keratitis - Pipeline by AmebaGone Inc, H2 2019
Keratitis - Pipeline by Cumulus Pharmaceutical LLC, H2 2019
Keratitis - Pipeline by Dobecure SL, H2 2019
Keratitis - Pipeline by Editas Medicine Inc, H2 2019
Keratitis - Pipeline by Eleusis Ltd, H2 2019
Keratitis - Pipeline by EyeGate Pharmaceuticals Inc, H2 2019
Keratitis - Dormant Projects, H2 2019
Keratitis - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Keratitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AlfaSigma SpA
  • AmebaGone Inc
  • Cumulus Pharmaceutical LLC
  • Dobecure SL
  • Editas Medicine Inc
  • Eleusis Ltd
  • EyeGate Pharmaceuticals Inc
  • Fox Chase Chemical Diversity Center Inc
  • iVeena LLC
  • MimeTech Srl
  • NanoViricides Inc
  • RegeneRx Biopharmaceuticals Inc
  • Riptide Bioscience Inc
  • Shulov Innovative Science Ltd
  • SIFI SpA
  • Sinsa Labs Inc
  • TGV-Inhalonix Inc
  • Veloce BioPharma LLC
  • Viraze
Note: Product cover images may vary from those shown
Adroll
adroll